Most published data on survival in sarcomas relates to selected patients referred to specialist treatment centres (Markhede et al., 1982; Bramwell et al., 1985; Collin et al., 1987; Stotter et al., 1990; El-Jabbour et al., 1990) . Survival data from other, more broadly-based groups, have not relied upon centrally reviewed histological diagnoses for all the cases included (Tucker & Fraumeni, 1982; Fraumeni & Boice, 1982) . Exceptions to these generalisations are certain childhood series which relate to defined populations and include special histopathological review of all cases ascertained (Craft et al., 1987; Birch et al., 1988 ) and a recently reported population-based study of malignant fibrous histiocytoma from the southern health care region of Sweden (Rooser et al., 1991) .
Soft tissue and bone sarcomas are rare tumours and, because of the wide variety of sub-types and sites of tumour which are seen, estimation of survival is difficult. Added to this is the observation that histopathological review often results in change in diagnosis of sub-type and may even result in certain tumours being redesignated as non-sarcomas (Presant et al., 1986; Alvegard & Berg, 1989 , El-Jabbour et al., 1990 Agnarsson et al., 1991) .
The cases reported here, ascertained over a 3-year period from a defined geographical region, have been subjected to histopathological review by a panel of five pathologists. Follow-up to ascertain vital status over a 5 year period was almost complete and this paper reports the patterns of survival seen.
Methods
All cases of sarcomas notified to the North Western Regional Cancer Registry for the period 1982-1984 together with those cases, which on individual scrutiny appeared to have been considered as possible sarcomas, were ascertained for the study. A more detailed description of ascertainment is given elsewhere . Cases included for histopathological review were those malignant soft tissue tumours (including visceral tumours) listed by Enzinger and Weiss (1988) . Because of the variability in the amount and quality of the material received, grade of malignancy could not be specified, nor was information about tumour stage or the presence of metastatic disease available for the study.
Final diagnoses were coded using ICD-0 (WHO, 1976 (Kaplan & Meier, 1958) . 95% confidence intervals were calculated for 5-year survival rates and survival curves were compared using the log rank test (Peto et al., 1977 Observed survival curves were divided by those expected to obtain relative survival curves which were compared using an additive model for the hazards (Buckley, 1984) . The computer package Epilog Plus, version 2, was used for all the statistical analyses (1987) .
Results
Out of a total of 59,784 cancer registrations for the North Western Region for the years 1982-84, 450 cases were registered as sarcomas and 313 of these were confirmed as such on panel review. From the additional 18 cases selected because of uncertain malignancy or because of mention of sarcoma as a differential diagnosis or cause of death on the registration form, two were confirmed as sarcomas by the panel. For this analysis five cases were excluded from the 315 reviewed cases with a final diagnosis of sarcoma: on further scrutiny four were found to have been originally diagnosed outside the NWRHA area and one case had diagnosis date incorrectly notified. Distribution by histological type for the 310 cases included in the survival analyses are shown in Table I .
An additional 38 cases (Table II) were included in some analyses. These included 19 clinically-diagnosed cases; 13 cases where no material was received or could be obtained from the fixed material sent; and six cases where histological material was received but no diagnosis could be made by the panel.
All surviving cases, except one, were successfully 'flagged' on the NHSCR so that current vital status was available. For the non-flagged case the date last seen was abstracted from hospital notes and was taken as the date of the last follow up.
Crude survival curves for all sarcomas and for certain subgroups are shown in Figures 1-8 and a summary of crude and relative survival for the major sites and histological groups is given in Table III . Survival rates quoted are those at 5 years and the P values are those comparing the entire survival curves. Comments in general refer to reviewed cases except where any striking differences emerged when non-reviewed cases were taken into consideration, and to crude survival, rather than relative survival, other than where age was a consideration. Where ages other than median ages have been used for analysis, these have also been shown in Table III .
The 5-year survival rate for all reviewed sarcoma patients was 34% and there was no statistically significant difference in survival between males and females (P = 0.6, males 32%, females 36%) (Figure 1) . Survival, however, was significantly worse for patients diagnosed over the median age of 60 years (P = < 0.0001, < 60 yrs 43%, > 60 yrs 24%) (Figure 2) and this difference persisted when the rates were corrected for underlying mortality (P = 0.03, relative survival < 60 yrs 44%, > 60 yrs 34%).
Stratification by site of tumour ( Figure 3 ) revealed a higher rate of survival in patients with bone tumours (44%) than for those with sarcomas of female genital tract (35%), of nonvisceral soft tissue and miscellaneous sites (32%) and of gastro-intestinal tract (13%). Numbers in the last category were, however, very small and the overall difference in survival by site was only of borderline significance (P= 0.08). The differences were less marked when relative survival was considered (P = 0.2). The survival of males and females with tumours of non-visceral soft tissue and miscellaneous sites was very similar (P = 0.4). Two of the five female patients with a tumour of the gastro-intestinal tract survived 5 years but all of the ten male patients died within 3 years (P = 0.08). Male patients with bone sarcomas had a marginally better survival than female patients but this difference did not attain statistical significance (P = 0.3).
Further sub-division of patients with tumours of nonvisceral soft tissue into those with tumours of head, neck and trunk; extremities or retroperitoneum showed a statistically significant difference in survival between these sites (P= 0.03). This finding was related mainly to the very poor survival of patients with retroperitoneal tumours (5-year survival = 15%). There were no significant differences in survival by sex of patient for these three site sub-groups.
Stratification by age within the major sites indicated that crude survival appeared consistently better for the younger patients but the difference only attained statistical significance for non-visceral soft tissue combined with miscellaneous sites and for female genital tract. Five-year crude survival for the former group was 38% in patients aged under 65 years at diagnosis compared with 25% for those aged 65 years and over (P = 0.04). Difference in survival by osteosarcoma and chondrosarcoma, were very similar with the greatest mortality in both occurring in the first 2-3 years. There was no significant difference for either sub-type by sex of patient but markedly different patterns emerged when the data were stratified by age at diagnosis, possibly because of the wide difference in the median age at diagnosis in the two groups. Osteosarcoma patients diagnosed under age 20 years had more than twice the 5-year survival rate than those diagnosed over this age (P = 0.01, 62% vs 27%) (Figure 7) , a --------------I-ltinerence which was also apparent in relative survival rates -------------(P = 0.02, 62% vs 34%). For patients with chondrosarcoma the difference in survival by age was not significant, but the numbers studied were small. median age at diagnosis for the group as a whole (29 the study . Inclusion of these ineligible and a much greater survival differential with 56% cases in any non-reviewed series may bias survival data. ,urvival at 5 years for those aged less than 30 years at Many studies have investigated prognostic variables for sis and 11% for those aged 30 years and over survival in sarcomas. Most of these have either concentrated 0004). Relative survival was 56% vs 15% (P = 0.002).
upon features of the tumour itself, i.e. histological grade, size, depth, degree of necrosis etc. (Trojani et al., 1984; Rooser et al., 1988; Ueda et al., 1988; Mandard et al., 1989) [ion or on various treatment modalities (Markhede et al., 1982; Bramwell et al., 1985; Suit et al., 1985) . In addition, most of tl in sarcoma patients is difficult to assess reliably these observations have been made on hospital-based or on of the rarity of such tumours, their differing toposelected sub-sets of population-based series. -al sites, the wide range of histological types seen and Grading of tumours was not part of the protocol for this fculty of assessing degree of malignancy in certain study so each group of sarcomas considered here is very As a result of these factors, most published series mixed with respect to malignant potential. Nor was informhave included special pathology review have reported ation on the presence of metastatic disease generally available certain proportion of cases have been eliminated at the time of case ascertainment. Hence the results represent ient to re-classification as malignant tumours other a broad generalisation in terms of survival. In addition, Lrcomas, connective tissue tumours of borderline or because of the small numbers of some histological types the vin malignant potential, benign tumours or nonpower of the study to detect differences in survival within tic conditions (Presant et al., 1986; AlvegArd & Berg, and between groups was low in some cases. 1-Jabbour et al., 1990 , Agnarsson et al., 1991 . This is
Overall 5-year survival for the patients with reviewed histoe case in the present series where a non-sarcoma logy entered in this series was 34%. In general, survival for is was made in 22% of the cases originally entered in bone sarcomas was marginally better than that for soft tissue tumours of any specified site i. (Enzinger & Weiss, 1988) .
Comparison with the population-based series of MFH 0.50 reported from Sweden (Rooser et al., 1991) indicated that --------5 survival in our series was much poorer (29% vs 72%) and L----- that the very marked survival differential between younger ---and older patients was not apparent in the Swedish series. overall had a slightly better 5-year survival rate than males (36% vs 32%), the difference was reversed for bone tumour patients (51% vs 32%) but neither difference was statistically significant. Better survival in female soft tissue sarcoma patients has been noted by R66ser et al. (1988) , Ueda et al. (1988) and El-Jabbour et al. (1990) , but no difference was apparent in other series (Bramwell et al., 1985; Collin et al., 1987) . The most consistent finding in these analyses was the better prognosis for younger patients as reported by other investigators (Bramwell et al., 1985; Collin et al., 1987; ElJabbour et al., 1990) . Five year relative survival for patients who were under the median age at diagnosis of 60 years was 44% as opposed to 34% in those aged 60 years and over (P = 0.03). This survival differential was particularly striking for sarcomas (including leiomyosarcoma) of female genital tract, for MFH, osteosarcoma of bone and sarcoma NOS.
0.25----------------------------
The wide divergence in survival between younger and older patients with osteosarcoma when all non-reviewed cases are taken into consideration is explained largely by the inclusion of a group of elderly patients, most of them male and with tumours associated with Paget's disease of bone in whom survival was particularly poor.
One of the encouraging results to emerge from the study was the high level of survival in children and young adults with osteosarcoma (62% at 5 years for patients aged under 20 years at diagnosis), a feature noted by Birch et al. (1988) for younger children registered with the Manchester Children's Tumour Registry, some of whom were also entered in this study. The improved level of survival for osteosarcoma in young people may be a reflection of the increasing trend towards the centralisation of treatment of childhood cancer in Britain which has been shown to have a favourable effect on survival for the period 1977-84 (Stiller, 1988) . Most children and young adults in the North West region are treated centrally by consultants who are members of the United Kingdom Children's Cancer Study Group.
No analysis in general of survival by treatment centre was possible for patients in this series. Although a high proportion of patients was seen at the Christie Hospital and Holt Radium Institute, the major cancer treatment centre in the North Western region, no consistent information was available on reason for referral, i.e. for initial diagnosis, primary treatment, treatment of recurrence or palliation. Nor were treatment details available. Hence no comment can be made on how the survival patterns described here relate to primary treatment or adjuvant therapies.
The overall survival rates presented here may seem depressingly poor, especially those for the soft tissue tumours. It is important to bear in mind, however, that this series encompasses all cases from the North Western region, including those who were diagnosed at post mortem or died before treatment could be instituted, those who were considered too old or ill for active treatment, and those not referred to a primary treatment centre or referred only at the time of development of metastatic disease. Hence, although the study looked at a limited range of prognostic variables, i.e. histological type, site, age and sex, because it was truly population-based and included peer-review of histology, the results give a realistic assessment of overall survival for different types of sarcomas.
